GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » ROC %

Mycenax Biotech (ROCO:4726) ROC % : -10.95% (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Mycenax Biotech's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was -10.95%.

As of today (2025-04-05), Mycenax Biotech's WACC % is 1.59%. Mycenax Biotech's ROC % is -15.05% (calculated using TTM income statement data). Mycenax Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Mycenax Biotech ROC % Historical Data

The historical data trend for Mycenax Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech ROC % Chart

Mycenax Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.19 -4.77 -14.84 -20.29 -15.05

Mycenax Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.25 -18.45 -14.05 -16.79 -10.95

Mycenax Biotech ROC % Calculation

Mycenax Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=-461.483 * ( 1 - 0.52% )/( (3020.443 + 3081.414)/ 2 )
=-459.0832884/3050.9285
=-15.05 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3770.401 - 405.371 - ( 668.886 - max(0, 753.423 - 1098.01+668.886))
=3020.443

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3368.376 - 212.077 - ( 278.065 - max(0, 661.496 - 736.381+278.065))
=3081.414

Mycenax Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-366.78 * ( 1 - 8.12% )/( (3071.666 + 3081.414)/ 2 )
=-336.997464/3076.54
=-10.95 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3477.766 - 222.367 - ( 404.817 - max(0, 644.103 - 827.836+404.817))
=3071.666

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3368.376 - 212.077 - ( 278.065 - max(0, 661.496 - 736.381+278.065))
=3081.414

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mycenax Biotech  (ROCO:4726) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Mycenax Biotech's WACC % is 1.59%. Mycenax Biotech's ROC % is -15.05% (calculated using TTM income statement data). Mycenax Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Mycenax Biotech ROC % Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycenax Biotech Business Description

Traded in Other Exchanges
N/A
Address
No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines